Gainers

• Lisata Therapeutics (NASDAQ:LSTA) stock rose 37.2% to $1.4 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million.
• BioStem Technologies (NASDAQ:BSEM) shares moved upwards by 32.21% to $1.38. The market value of their outstanding shares is at $19.4 million.
• CervoMed (NASDAQ:CRVO) stock increased by 31.02% to $1.79. The market value of their outstanding shares is at $20.7 million. As per the press release, Q3 earnings came out 3 days ago.
• Cellectis (NASDAQ:CLLS) stock rose 28.82% to $1.43. The company's market cap stands at $111.8 million.
• Yarrow Bioscience (NASDAQ:YARW) shares increased by 22.73% to $19.0. The market value of their outstanding shares is at $130.6 million.
• Cumberland Pharma (NASDAQ:CPIX) stock rose 21.88% to $6.46. The company's market cap stands at $79.4 million. The company's, Q3 earnings came out yesterday.

Losers

• Basel Medical Group (NASDAQ:BMGL) stock declined by 64.5% to $0.69 during Wednesday's regular session. The company's market cap stands at $26.2 million.
• Aptevo Therapeutics (NASDAQ:APVO) stock decreased by 30.15% to $0.75. The market value of their outstanding shares is at $1.9 million.
• SL Science Holding (NASDAQ:SLBT) stock decreased by 24.97% to $0.67. The company's market cap stands at $504.1 million.
• Bio Green Med Solution (NASDAQ:BGMS) stock fell 24.81% to $0.6. The market value of their outstanding shares is at $5.3 million.
• Eocene (NASDAQ:EOCN) stock fell 20.38% to $2.15. The company's market cap stands at $2.8 million.
• Autonomix Medical (NASDAQ:AMIX) shares fell 20.01% to $1.48. The company's market cap stands at $3.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.